Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain

Vaccine. 2005 Jul 14;23(32):4097-100. doi: 10.1016/j.vaccine.2005.03.045.


This study describes the epidemiological impact of meningococcal C conjugate vaccine on age groups targeted by this vaccination programme in Spain, and estimates high short-term vaccine effectiveness values under field conditions in the 4 years following its introduction. Meningococcal C conjugate vaccine has led to a substantial reduction in incidence of meningococcal serogroup C disease in Spain among age groups targeted for intervention nationwide. Disease surveillance in the 4 years since the vaccine was introduced has enabled vaccine effectiveness (VE) to be estimated. The vaccine registered high short-term VE values but there has been some loss of VE with time. Four years after vaccination, vaccine protection levels exceeded 94% in cohorts immunised during the campaign. Among children vaccinated in routine childhood immunisation programmes, however, long-term VE loss was greater. Accordingly, there is a need for ongoing re-evaluation of VE and ascertainment of long-term vaccine protection. The findings reported would allow to decide on the advisability of revising current vaccination guidelines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Immunization Programs
  • Mass Vaccination
  • Meningococcal Infections / epidemiology
  • Meningococcal Infections / prevention & control*
  • Meningococcal Vaccines / administration & dosage*
  • Meningococcal Vaccines / immunology
  • Neisseria meningitidis, Serogroup C / immunology*
  • Spain / epidemiology
  • Treatment Outcome
  • Vaccines, Conjugate / administration & dosage*
  • Vaccines, Conjugate / immunology


  • Meningococcal Vaccines
  • Vaccines, Conjugate